CFTR and cystic fibrosis: Here, in a clinical trial, the authors show that CFTR-modulator therapy reshapes the lung and gut microbiomes in cystic fibrosis, reducing bacteria such as Staphylococcus in the lungs and Escherichia in stool, and showing that microbiome dysbiosis can be partially reversed.